PITTSBURGH, Oct. 29, 2013 /PRNewswire/ -- Cohera Medical, Inc. ®, a leading innovator and developer of absorbable surgical adhesives and sealants, was named a Health Care Hero by the Pittsburgh Business Times, a recognition that honors individuals and organizations in western Pennsylvania's health care industry.
Cohera Medical was recognized for its work with TissuGlu® Surgical Adhesive, Sylys® Surgical Sealant, and the strong leadership from President and CEO, Patrick Daly at the October 23rd event at the Omni William Penn in Pittsburgh.
"It is a great honor to be recognized among the region's most innovative health care organizations. Cohera Medical is a small organization with a vision to transform the post operative experience for patients, surgeons and hospitals," said Cohera Medical President and CEO, Patrick Daly.
Alan Robertson, publisher of the Pittsburgh Business Times, congratulated Cohera Medical on the achievement, "The Health Care Heroes awards are a great way to shine a spotlight on amazing people and organizations in our region. I'm always impressed by the commitment, dedication and skills of the people honored by this award."
The Pittsburgh Business Times and presenting sponsor Highmark, hosted a gala dinner on October 23rd to celebrate the people and organizations in Pittsburgh's regional health care industry who are instrumental in making this region one of the premier health care centers in the world. The 2013 Health Care Heroes were selected by an independent panel of judges, all of whom are experts in the health care industry.
About Cohera Medical
Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company's first product, TissuGlu® Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that eliminates or reduces fluid accumulation and the need for post surgical drains. TissuGlu's chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery.
TissuGlu has received CE Marking approval to be sold in the European Union (EU). Cohera Medical is also developing a unique and proprietary bowel sealant, and a strong adhesive for mesh fixation. Outside of the EU, TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for medical use by the Food and Drug Administration (FDA) in the U.S. or in any other market. For more information, visit www.coheramed.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
SOURCE Cohera Medical, Inc.